Analytical Data
-
Gene name
CCL21a
- Application
-
Alternative Names
CCL21a；Scya21；C-C motif chemokine 21a
-
Species
Mouse
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P84444
-
Expression Region
24-133aa
-
AA Sequence
SDGGGQDCCL KYSQKKIPYS IVRGYRKQEP SLGCPIPAIL FSPRKHSKPE LCANPEEGWV QNLMRRLDQP PAPGKQSPGC RKNRGTSKSG KKGKGSKGCK RTEQTQPSRG
-
Molecular Weight
12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL21a, a member of the CC chemokine family, plays a crucial role in immune system regulation and inflammation. It is primarily involved in the trafficking of lymphocytes and dendritic cells to lymph nodes, facilitating adaptive immune responses. Research has shown that CCL21a interacts with its receptor, CCR7, to promote the migration of T cells and other immune cells, which is vital for establishing effective immune surveillance and response to infections and tumors. Given its significant role in immunology, CCL21a has drawn attention as a potential therapeutic target in various conditions, including cancer, autoimmune diseases, and chronic inflammation. Recombinant CCL21a protein has been developed for research purposes to further elucidate its mechanisms of action, explore its potential in immunotherapy, and evaluate its role in lymphocyte migration and activation. The study of CCL21a not only enhances our understanding of cellular communication in the immune system but also provides insights into how modulation of this pathway could lead to innovative treatment strategies for immune-related disorders.
